<DOC>
	<DOC>NCT01356680</DOC>
	<brief_summary>This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS).</brief_summary>
	<brief_title>HD17 for Intermediate Stage Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Hodgkin Lymphoma CS I, II with risk factor (stage IIB with risk factor 1 or 2 are not included) large mediastinal mass (&gt;1/3 of maximum transverse thorax diameter) extranodal involvement elevated ESR 3 or more involved nodal areas written informed consent Leucocytes &lt;3000/µl Platelets &lt; 100000/µl Hodgkin Lymphoma as composite lymphoma Activity Index (WHO) &gt;2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>intermediate stage</keyword>
	<keyword>PET</keyword>
</DOC>